KDR and neoplasm: Targeting the VEGF–VEGFR axis including anti-VEGF monoclonal antibodies (e.g., bevacizumab) and VEGF receptor inhibitors (e.g., SU5416) has been developed for anti-tumor induced angiogenesis [48].